Crinetics Pharmaceuticals (CRNX) News Today

Sei Investments Co. increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 75.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,669 shares of the company's stock after

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $53.43, for a total transaction of $160,290.00. Following the sale, the insider now owns 75,611 shares in the company, valued at $4,039,895.73. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CFO Marc Wilson sold 19,056 shares of the company's stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $53.88, for a total transaction of $1,026,737.28. Following the transaction, the chief financial officer now owns 111,092 shares of the company's stock, valued at approximately $5,985,636.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Russell Investments Group Ltd. boosted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 366,571.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,334 shares of th

Seven Eight Capital LP lessened its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 41.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 20,510 shares of the company's stock after selling 14,402 shares during the period. Seven E

Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High at $55.78

Swiss National Bank lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,500 shares of the company's stock after purcha

Lord Abbett & CO. LLC grew its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 24.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 964,568 shares of the company's stock after acquiring an add

BNP Paribas Financial Markets lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 74.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,960 shares of the company's s

Lisanti Capital Growth LLC trimmed its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 30.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,225 shares of

Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 12-Month High at $54.16

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and eleven have assigned a buy ratin

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider James Hassard sold 15,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $44.08, for a total value of $661,200.00. Following the completion of the sale, the insider now owns 29,259 shares of the company's stock, valued at $1,289,736.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading 4.1% Higher on Analyst Upgrade

JPMorgan Chase & Co. boosted their price target on shares of Crinetics Pharmaceuticals from $47.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday.

Jennison Associates LLC grew its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,817,854 shares of the c

Vanguard Group Inc. increased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,502,452 shares of the company's stock after buying an additional 95,417 shares dur

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 14,375 shares of the firm's stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $44.87, for a total value of $645,006.25. Following the transaction, the insider now directly owns 28,507 shares in the company, valued at approximately $1,279,109.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Piper Sandler restated an "overweight" rating and set a $97.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Tuesday.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 5,860,000 shares, a growth of 16.5% from the May 31st total of 5,030,000 shares. Based on an average daily volume of 878,700 shares, the days-to-cover ratio is currently 6.7 days.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) COO Jeff E. Knight sold 956 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $44.38, for a total value of $42,427.28. Following the completion of the sale, the chief operating officer now owns 52,580 shares in the company, valued at $2,333,500.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Crinetics Pharmaceuticals in a research note on Friday.

Goldman Sachs Group Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 17.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 650,173 shares of the company's stock after acquiring an additional 97,575

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider James Hassard sold 15,000 shares of the company's stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $44.66, for a total value of $669,900.00. Following the completion of the transaction, the insider now owns 29,259 shares in the company, valued at $1,306,706.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Wellington Management Group LLP lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,245,105 shares of the company's stock after

Fisher Asset Management LLC lifted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 719.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 441,295 shares of the company's stock after acquiring an

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven ha

Opaleye Management Inc. cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 307,500 shares of the company's stock after selling 62,500 sha

Parkman Healthcare Partners LLC raised its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 20.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 120,652 shares of the company's stock after buying

First Light Asset Management LLC increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 25.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,987,772 shares of the company's stock after purchasing an add

Point72 Asset Management L.P. lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 19.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,416,900 shares of the company's stock afte

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 3,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $43.86, for a total transaction of $131,580.00. Following the sale, the insider now directly owns 83,643 shares of the company's stock, valued at approximately $3,668,581.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Seven Eight Capital LP acquired a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 34,912 shares of the

Rafferty Asset Management LLC lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 244,289 shares of the company's stoc

TD Asset Management Inc raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 26.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 176,426 shares of the company's stock after acquiring an a